FRANKFURT, Nov 19 (Reuters) - Bayer on Tuesday struck a collaboration deal with U.S. biotech firm Cytokinetics to acquire certain rights in Japan to an experimental heart drug, as the German group strengthens its cardiovascular business with smaller deals.
Cytokinetics will receive 50 million euros ($53 million) upfront, plus up to 90 million euros contingent on certain development achievements, Bayer said in a statement.
Cytokinetics also stands to receive up to 490 million euros from Bayer, depending on certain sales milestones.
The deal covers certain uses of drug candidate aficamten in hypertrophic cardiomyopathy, an inherited condition that limits the heart’s pumping function.
German diversified group Bayer, which is burdened by debt, weak agriculture markets and costly litigation, has faced investor calls to boost its drug development pipeline.
In March, Bayer acquired European commercialization rights for heart drug acoramidis for up to $310 million from a group of companies.
($1 = 0.9448 euros)
(Reporting by Ludwig Burger, Editing by Friederike Heine)
((ludwig.burger@thomsonreuters.com; +49 30 220133634;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.